Further investigation is warranted to elucidate the precise mechanisms by which MAU2 contributes to the pathogenesis and progression of NAFLD, as well as the therapeutic advantages of targeting this pathway for enhanced treatment modalities. Here, MAU2 is linked to metabolic dysfunction-associated steatotic liver disease.